Onward Medical ARC-EX sales surge 5x; cash rises to EUR 81.5m
ARC-EX sales increased 5x year-over-year, with a 250% revenue increase. Cash strengthened to EUR 81.5 million, supporting pivotal trials and commercialization. Interim Empower BP results expected in early 2027.
S. and Europe and a 250% increase in revenue. 5 million, backing ongoing pivotal trials and commercialization efforts. Interim Empower BP results are expected in early 2027.